MINAPRINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H22N4O
Molecular Weight	298.3828
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3

InChI

InChIKey=LDMWSLGGVTVJPG-UHFFFAOYSA-N

InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3836113 | https://www.ncbi.nlm.nih.gov/pubmed/7862862 | https://www.ncbi.nlm.nih.gov/pubmed/3954800 | https://www.ncbi.nlm.nih.gov/pubmed/2975224

Minaprine, a psychotropic drug, which was effective in the treatment of various depressive states. This drug was withdrawn because of the serious side effect. It was found, that minaprine inhibited the following enzymes, acetylcholinesterase and monoamine oxidase (MOA) A. It also binds to dopamine D1 and D2 receptors. Experiments on rodents also have revealed that minaprine suppressed the inhibitory effect of hydroxytryptamine (5-HT) on dopamine (DA) release via the inhibition of 5-HT binding at the 5-HT2 receptor on the nerve terminal.

Approval Year

Targets

Primary Target	Pharmacology	Potency
Acetylcholinesterase 207 Target ID: CHEMBL3199 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10052979	Inhibitor 8297	85.0 µM [IC50]
Muscarinic acetylcholine receptor M1 169 Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14998318\|https://www.drugbank.ca/drugs/DB00805	Agonist 2678	17.0 µM [Ki]
Monoamine oxidase A 49 Target ID: CHEMBL3358 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2531423\|https://www.ncbi.nlm.nih.gov/pubmed/3954800	Inhibitor 8297	1.0 mM [IC50]
Dopamine D1 and D2 receptor 2 Target ID: CHEMBL2111341 Sources: https://www.drugbank.ca/drugs/DB00805\|https://www.ncbi.nlm.nih.gov/pubmed/7862862\|https://www.ncbi.nlm.nih.gov/pubmed/3836113	Agonist 2678
Serotonin 2 (5-HT2) receptor 87 Target ID: CHEMBL2093870 Sources: https://www.drugbank.ca/drugs/DB00805\|https://www.ncbi.nlm.nih.gov/pubmed/2530096\|https://www.ncbi.nlm.nih.gov/pubmed/2975224\|https://www.ncbi.nlm.nih.gov/pubmed/3419543	Antagonist 2778

PubMed

Title	Date	PubMed
Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug.	1982	6890359
Toxic cocaine- and convulsant-induced modification of forced swimming behaviors and their interaction with ethanol: comparison with immobilization stress.	2002 Nov 9	12425723
Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6.	2003 Dec 1	14642599
3-Benzidino-6(4-chlorophenyl) pyridazine blocks delayed rectifier and transient outward potassium current in acutely isolated rat hippocampal pyramidal neurons.	2006 Jul 10	16647816
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.	2007 Sep 4	17784957
Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database.	2009 Nov	19661215

Sample Use Guides

In Vivo Use Guide

minaprine 100 mg, 200 mg or 300 mg day-1 . The drug was administered for 6 weeks

Route of Administration: Oral

Name

Type

Language

MINAPRINE

Official Name

English

minaprine [INN]

Common Name

English

MINAPRINE [MI]

Common Name

English

AGR-1240

Code

English

Minaprine [WHO-DD]

Common Name

English

4-MORPHOLINEETHANAMINE, N-(4-METHYL-6-PHENYL-3-PYRIDAZINYL)-

Systematic Name

English

MINAPRINE [USAN]

Common Name

English

4-[2-[(4-Methyl-6-phenyl-3-pyridazinyl)amino]ethyl]morpholine

Systematic Name

English

CB-30038

Code

English

CANTOR

Brand Name

English

Classification Tree Code System Code

WHO-ATC

N06AX07